KM Biologics’ mpox vaccine approved for emergency use by WHO
The first mpox vaccine authorised for children will be shipped to DRC in a 3.05 million-dose donation by the Japanese Government.
Therapy Area
Tris Pharma receives ex-US approvals for ADHD treatments
Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab
Aclaris Therapeutics secures global rights to Biosion’s antibodies
ReCode to secure funds for cystic fibrosis gene correction treatments
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
FDA approves Syndax’s Revuforj to treat leukaemia
AHA 2024: lerodalcibep provides promising results in open-label extension trial, LIBERATE-OLE
